The Integrating Medications for Addiction Treatment (IMAT) Index: A measure of capability at the organizational level.

Journal of Substance Abuse Treatment
Helene Chokron GarneauMark P McGovern

Abstract

Primary care provides a treatment opportunity for many persons with opioid use disorder (OUD). The push to integrate and expand reach and adoption of medications for opioid use disorder (MOUD) within primary care has been a major focus of national, state and health systems endeavors. To guide high capability MOUD practice, we introduce the Integrating Medications for Addiction Treatment (IMAT) Index. The research team has developed IMAT along similar lines to other organizational measures of integrated services capability. We present the development and validation of the measure, and suggest its applicability for systems and organizations, as well as for process improvement and implementation research. Forty-one primary care clinics completed the IMAT at two time points: baseline and 9-month follow-up. Findings support the IMAT Index as psychometrically acceptable and pragmatically useful. It has good internal consistency, as well as concurrent and predictive validity. Changes in IMAT scores between baseline and follow-up significantly predicted increases in proportion of patients on MOUD. The IMAT has the potential to support both scientific and public health care activities.

References

Sep 4, 1999·American Journal of Public Health·R E GlasgowS M Boles
Feb 24, 2006·Journal of the American Board of Family Medicine : JABFM·Russell E Glasgow
Oct 26, 2006·Medical Care·Thomas E OxmanMartha L Bruce
Nov 26, 2009·Drug and Alcohol Review·Nicole Lee, Jacqui Cameron
Jan 5, 2011·Administration and Policy in Mental Health·Gregory A AaronsSarah McCue Horwitz
Mar 2, 2011·Journal of Addiction Medicine·Hannah K KnudsenPaul M Roman
Jan 16, 2013·Journal of Substance Abuse Treatment·Stanley SacksJacqueline Martinez
Jan 22, 2013·The Journal of Behavioral Health Services & Research·Heather J GothamRonald E Claus
May 21, 2013·Journal of Dual Diagnosis·Howard PadwaChristine E Grella
Sep 28, 2013·Journal of Dual Diagnosis·Gary R Bond, Mark P McGovern
Jun 15, 2014·The Journal of Behavioral Health Services & Research·Michael Chaple, Stanley Sacks
Nov 15, 2015·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Aaron D FoxChinazo O Cunningham
Dec 6, 2016·Annals of Internal Medicine·P Todd KorthuisRoger Chou
Jun 27, 2011·International Journal of Medical Education·Mohsen Tavakol, Reg Dennick
Apr 2, 2017·Drug and Alcohol Dependence·Hannah K KnudsenSharon L Walsh
Jan 16, 2018·Progress in Community Health Partnerships : Research, Education, and Action·Katherine E WatkinsHarold Alan Pincus
Jun 6, 2018·Journal of Substance Abuse Treatment·Allison J OberSarah B Hunter
Jun 10, 2018·BMC Health Services Research·James H FordMark P McGovern
Jun 19, 2018·Journal of Substance Abuse Treatment·Arthur Robin WilliamsMark Olfson
Oct 26, 2018·Annals of Internal Medicine·Stephen A MartinAmanda Wilson
Jan 25, 2019·The American Journal of Drug and Alcohol Abuse·Arthur Robin WilliamsMark Olfson
Nov 27, 2019·BMC Health Services Research·Kim A HoffmanDennis McCarty
Jan 8, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Amanda J AbrahamPeter D Friedmann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.